Boston Scientific's fourth-quarter net income and sales rose and the medical-device maker projected more growth in 2026 amid robust demand for cardiovascular products.

Investors had anticipated an even stronger forecast. Shares of BosSci fell 8.3% to $84 premarket.

The Marlborough, Mass., maker of medical devices such as stents and defibrillator implants logged earnings of $672 million, or 45 cents a share, up from $562 million, or 38 cents a share, a year earlier.

Adjusted earnings rose to 80 cents a share compared with mean analyst estimates of 78 cents a share as per FactSet.

Sales rose 16% to $5.29 billion, edging the average Wall Street forecast of $5.28 billion, according to FactSet. Sales at the cardiovascular unit rose 18% to $3.48 billion, while MedSurg sales increased 12% to $1.81 billion.

For the first quarter, BosSci targeted adjusted earnings in a range between 78 cents and 80 cents a share, with sales growth of about 10.5% to 12%, or 8.5% to 10% on an organic basis, excluding the impact of skew factors such as acquisitions and foreign exchange.

For 2026, the stent maker forecast adjusted earnings in a range between $3.43 and $3.49 a share, up from $3.06 a share in 2025. The company anticipates sales growth of 10.5% to 11.5% for the year, or 10% to 11% on an organic basis.